Hypertension in an urban HIV-positive population compared with the general population: influence of combination antiretroviral therapy
Authors:
- Morten BaekkenMBMorten Baekken
- Ingrid OsIOIngrid Os
- Leiv SandvikLSLeiv Sandvik
- Olav OektedalenOOOlav Oektedalen
- 1 November 2008
- journal article
- research article
- Published by Wolters Kluwer Health in Journal Of Hypertension
- Vol. 26 (11) , 2126-2133
Abstract
Hypertension is a major risk factor for cardiovascular diseases and mortality. The introduction of combination antiretroviral therapy for HIV-infected patients has changed their prognosis substantially, but there is an additional cost from the increased risk of cardiovascular diseases. We aimed to assess the prevalence of hypertension in an HIV-infected population and to identify possible predictors. A cohort of 542 unselected HIV-infected individuals had their blood pressure measured at three consecutive clinical visits. They were compared with an age-matched, sex-matched and body mass index-matched population-based control group (n=24 968). The prevalence of hypertension among the white HIV-infected individuals was 36.5%, which was not significantly different from the general population. The mean diastolic blood pressure was higher in HIV-infected individuals. The highest prevalence of hypertension was found in those who had been treated by combination antiretroviral therapy for more than 5 years (44.4%). Patients with hypertension were characterized by older age, male sex, white ethnicity, higher body mass index, total cholesterol and low-density lipoprotein cholesterol, lower glomerular filtration rate, more frequent microalbuminuria, longer time with known HIV-positive status and longer combination antiretroviral therapy duration compared with normotensive individuals. Multivariate analysis revealed age, sex, body mass index, cholesterol, combination antiretroviral therapy duration and microalbuminuria as independent predictors of hypertension. Diastolic blood pressure was increased in these white HIV-infected patients compared with the general population, but there was no difference in the prevalence of hypertension. However, the duration of combination antiretroviral therapy predicted hypertension independently.Keywords
This publication has 44 references indexed in Scilit:
- AIDS-related vasculopathy: evidence for oxidative and inflammatory pathways in murine and human AIDSAmerican Journal of Physiology-Heart and Circulatory Physiology, 2005
- HIV Protease Inhibitors Activate the Unfolded Protein Response in Macrophages: Implication for Atherosclerosis and Cardiovascular DiseaseMolecular Pharmacology, 2005
- Lipoatrophic men 44 months after the diagnosis of lipoatrophy are less lipoatrophic but more hypertensiveHIV Medicine, 2005
- Causes of death among human immunodeficiency virus (HIV)-infected adults in the era of potent antiretroviral therapy: emerging role of hepatitis and cancers, persistent role of AIDSInternational Journal of Epidemiology, 2004
- Hypertension in HIV-1-infected patients and its impact on renal and cardiovascular integrityNephrology Dialysis Transplantation, 2004
- Prevalence of Hypertension in HIV-Positive Patients on Highly Active Retroviral Therapy (HAART) Compared with HAART-Na ve and HIV-Negative Controls: Results from a Norwegian Study of 721 PatientsEuropean Journal of Clinical Microbiology & Infectious Diseases, 2003
- Elevated Blood Pressure in HIV-Infected Individuals Receiving Highly Active Antiretroviral TherapyHIV Research & Clinical Practice, 2003
- Association between Protease Inhibitor Use and Increased Cardiovascular Risk in Patients Infected with Human Immunodeficiency Virus: A Systematic ReviewClinical Infectious Diseases, 2003
- Changing patterns of mortality across Europe in patients infected with HIV-1The Lancet, 1998
- Prevalence and Clinical Correlates of Microalbuminuria in Essential HypertensionHypertension, 1997